← All trials
NCT03064074
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2017
- Primary completion
- Jul 1, 2018
- Completion date
- Apr 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityOverall official - principal investigator
- Baylor UniversityStudy chair
- Baylor UniversityReponsible party - principal investigator
- Shriners Hospitals for ChildrenCollaborator
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Collaborator
- University of California, Los AngelesCollaborator
- University of NebraskaCollaborator
- Oregon Health and Science UniversityCollaborator
- University of South FloridaCollaborator
- Rockefeller UniversityCollaborator
- GenzymeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.